Targeted radiation beads show promise against eye cancer liver spread
NCT ID NCT01473004
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a treatment for uveal melanoma that has spread to the liver. Tiny radioactive beads were injected into the liver's blood vessels to deliver radiation directly to tumors. The goal was to shrink or control the liver tumors. 48 patients took part, and the study looked at how well the treatment worked and what side effects occurred.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
48 people
The number who actually took part.
- Started
-
Oct 2011
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * must have diagnosis of metastatic melanoma liver disease by histological confirmation * one measurable untreated or progressed liver lesion * less than 50% liver involvement * must have ECOG performance status of 0-1 * must have adequate renal and bone marrow function as: serum creatinine ≤ 2.0 mg/dl, granulocyte count ≥1000/mm3 and platelet count ≥100,000/mm3 * must have adequate liver function as: total bilirubin \<1.6 mg/ml and albumin \>3.0 g/dl Exclusion Criteria: * failure to meet any of the inclusion criteria * solitary liver metastasis that is amenable to surgical removal * previous treatment with isolated hepatic perfusion * systemic chemotherapy within 2 weeks of study entry * significant shunting to the lung (\>20%) as identified on Technetium-99m-macro-aggregated albumin nuclear medicine break-through scan * unsuccessful closure of collateral blood flows from the hepatic artery to non-targeted organs such as the GI tract * symptomatic liver failure including ascites and hepatic encephalopathy * metastasis outside of liver requiring systemic treatment within 3 months * untreated brain metastasis * main portal vein occlusion or inadequate collateral flow * uncontrolled hypertension or congestive heart failure * acute myocardial infarction within 6 months * medical complications with implication of less than 6 month survival * uncontrolled severe bleeding tendency or active GI bleed * significant allergic reaction to iodinated contrast * previous radiation that includes the liver in the main radiation field * pregnant or breast-feeding women * biliary obstruction, stent, or prior biliary surgery including sphincterotomy but excluding cholecystectomy * children under the age of 18
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Stage IV uveal melanoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States